Apellis SYFOVRE Sales Fall 4% on Rising Volume, Exposing a CVR Worth Zero

NEW YORK, April 1 —

SYFOVRE injection volumes rose 17% in 2025. Revenue fell 4% to $587mn. That gap tells you what Biogen actually bought — and what the CVR is actually worth.

What the Street Believes

The market treats $41/share as a fair-to-generous exit. The thesis: Biogen's larger salesforce fixes SYFOVRE's lagging commercial results. The CVR sweetens the deal.

That view ignores two things: the worsening gap between gross and net revenue, and two competitors arriving before the CVR window closes. At $40.23, the stock prices in near-certainty the base deal closes. The CVR is treated as a free lottery ticket.

What the Data Shows

The buried signal is the gross-to-net spread. More patients received SYFOVRE injections in 2025 than in 2024. But Apellis collected less per injection — enough to push total revenue down year over year.

"Apellis shareholders are eligible to receive up to an additional $4 per share via a non-transferable CVR if SYFOVRE achieves $1.5 billion in annual global net sales in any calendar year between 2027 and 2030, with an additional tier at $2 billion — milestones JPMorgan's model does not assume will be reached."

The math doesn't work. Reaching $1.5bn from $587mn requires a 155% jump in net sales. That means either tripling volume at stable prices or reversing copay assistance erosion — neither realistic with Iveric Bio's Izervay already on the market and Regeneron/Alnylam's C5 combination expected by late 2027.

The CVR's non-transferable structure is the quiet tell. Merger arbitrageurs can't strip it out and trade it separately. There's no independent price discovery, no liquid market to assign a probability-weighted value. Any residual option value sits locked inside the arb position, invisible.

Why This Changes the Calculus

If the CVR is worth zero — and JPMorgan's own model assumes exactly that — then the acquisition price is $41 flat. Street models range from $41 to $45 in total consideration. The data supports $41, period.

At $41/share, you're paying roughly $5.6bn for a business burning $15mn in TTM free cash flow. The entire growth case hangs on Empaveli's expansion into C3 glomerulopathy and other nephrology indications — a franchise that must carry a declining flagship product.

The number to watch: Q1 2026 SYFOVRE net revenue per injection. If the gross-to-net spread widens further, even $41 looks expensive. Each quarter of continued pricing erosion makes the Empaveli bet more binary.

The Counterargument

Biogen's infrastructure could improve SYFOVRE's commercial results. A larger salesforce, stronger payer negotiations, and international expansion could stabilize the gross-to-net trend. Empaveli's nephrology pipeline, particularly in C3 glomerulopathy, targets a genuine unmet need with limited competition.

The earnings trend shows improvement: Q2 2025 delivered $1.67 EPS versus $0.94 consensus, a 77.5% beat. That quarter proved operational leverage exists when volume converts to revenue.

But one strong quarter doesn't erase structural pricing decay. The 17%-volume-up, 4%-revenue-down split isn't a timing issue. It reflects payer dynamics a bigger salesforce can't fix. Biogen would need to overhaul SYFOVRE's entire copay architecture — mid-launch, mid-competition — to reverse the trend.

Verdict

The real acquisition price is not the headline $45. When Biogen announced the $5.6 billion deal, the CVR looked like real upside. The gross-to-net data says otherwise. At $41, you own a cash-flow-negative ophthalmology franchise facing two new competitors, plus an early-stage nephrology pipeline that needs to work perfectly to justify the price. The CVR is a rounding error dressed as optionality.